Litcius/Paper detail

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Aleksandra Syguła, Aleksandra Ledwoń, Kornelia Hasse-Lazar, Beata Jurecka‐Lubieniecka, Barbara Michalik, Ewa Paliczka-Cieślik, Marcin Zeman, Ewa Chmielik, Joanna Sczasny, Barbara Jarząb, Daria Handkiewicz-Junak

2022European Journal of Nuclear Medicine and Molecular Imaging14 citationsDOI

Topics & Concepts

Radionuclide therapyMedicineInternal medicineClinical endpointNeuroendocrine tumorsOctreotideSomatostatinGastroenterologyOncologySurgeryRandomized controlled trialNeuroendocrine Tumor Research AdvancesThyroid Cancer Diagnosis and TreatmentLung Cancer Research Studies
In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy | Litcius